|
Trial | Design | Agent | Planned Accrual | Inclusion Criteria (stage/grade) | Inclusion Criteria (histology) |
|
Adjuvant Trials |
|
IMmotion010, (NCT03024996) [29] | Prospective, double-blinded, placebo controlled | Atezolizumab | 664 | Nonmetastatic | Clear cell, sarcomatoid |
|
Checkmate-914, (NCT03138512) [22] | Prospective, double-blinded, placebo controlled | Nivolumab + Ipilimumab | 800 | pT2a – 4 N0 M0 (any), pT1-4 N1 M0 (any) | Clear cell |
|
Keynote-564, (NCT03142334) [23] | Prospective, double-blinded, placebo controlled | Pembrolizumab | 950 | pT2 N0 M0 (grade 4 or sarcomatoid), pT3-4 N0 M0 (any), pT1-4 N1 M0, Resectable M1 | Clear cell |
|
RAMPART, (NCT03288532) [30] | Prospective, multicenter, double-blinded, placebo controlled | Durvalumab, Durvalumab + tremelimumab | 1750 | Leibovich Score 3-11 | Any |
|
Neoadjuvant Trials |
|
Merck Sharp Dohme Corp (NCT02212730) [31] | Prospective, open label, parallel assignment | Pembrolizumab | 36 | cT1b+ NX-0 M0 | Any |
|
Bristol-Myers Squibb (NCT02575222) [32] | Prospective, open label | Nivolumab | 30 | cT2a-T4 NX-1 M0, cT1-4 N1 M0 | Clear cell |
|
NCI (NCT02595918) [33] | Prospective, open label | Nivolumab | 29 | Stage I-III | Clear cell |
|
Case Comprehensive Cancer Center (NCT02762006) [34] | Prospective, open label | Durvalumab, Tremelimumab | 45 | cT2b-4 NX-0 M0 cT1-4 N1, M0 | Any |
|
PROSPER, (NCT03055013) [35] | Randomized, double-blind, placebo controlled | Nivolumab | 766 | cT2 NX M0, cT1-4 N1 M0 | Any |
|
Roswell Park Cancer Institute (NCT02170389) [31] | Prospective, open label | RCC/CD40L RNA-Transfected Autologous Vaccine | 4 | pT1, NX-0, M0 | Any |
|